CoChat

Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products

Open access
Mebarki, Miryam, Abadie, Camille, Larghero, Jérôme, Cras, Audrey · 2021 · Stem Cell Research & Therapy
Cited by 223

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs) emerge as a perspective for therapeutic use in immune and inflammatory diseases. Indeed, immunomodulatory and anti-inflammatory properties, associated to fewer ethical, availability, and safety issues, position UC-MSCs as a promising active substance to develop medicinal products. Since 2007, UC-MSC-based products are classified as advanced therapy medicinal products (ATMP) according to the European Regulation 1394/2007/EC. This new regulatory status required a total adaptation of stakeholders wishing to develop UC-MSC-based ATMPs. Cell production in tissue and cell banks has been replaced by the manufacturing of a medicine, in authorized establishments, according to the good manufacturing practices (GMP) specific to ATMPs. After a brief description of UC-MSCs, we described in this review their recent use in a large panel of immune and inflammatory pathologies, including early and late phase clinical trials. Despite the use of the same product, we noticed an important heterogeneity in terms of indication, posology and study design. Then, we discussed regulatory and manufacturing challenges for stakeholders, especially in terms of process harmonization and cells characterization. Our aim was to point that despite MSCs use for several decades, the development of an UC-MSC-based ATMP remains at this day a real challenge for both academic institutions and pharmaceutical companies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13287-021-02222-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 48

  1. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 1995;16(4):557–64.
  2. Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–7. https://doi.org/10.1126/science.284.5411.143. · DOI · Paper page
  3. Lu L-L, et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica. 2006;91(8):1017–26.
  4. Ilancheran S, Moodley Y, Manuelpillai U. Human fetal membranes: a source of stem cells for tissue regeneration and repair? Placenta. 2009;30(1):2–10. https://doi.org/10.1016/j.placenta.2008.09.009. · DOI · Paper page
  5. Sabapathy V, Sundaram B, V M S, Mankuzhy P, Kumar S. Human Wharton’s Jelly Mesenchymal Stem Cells plasticity augments scar-free skin wound healing with hair growth. PLoS One. 2014;9(4):e93726. https://doi.org/10.1371/journal.pone.0093726. · DOI · Paper page
  6. Petrenko Y, et al. A comparative analysis of multipotent mesenchymal stromal cells derived from different sources, with a focus on neuroregenerative potential. Sci Rep. 2020;10(1):1. https://doi.org/10.1038/s41598-020-61167-z. · DOI · Paper page
  7. de Witte SFH, et al. Cytokine treatment optimises the immunotherapeutic effects of umbilical cord-derived MSC for treatment of inflammatory liver disease. Stem Cell Res Ther. 2017;8(1):140. https://doi.org/10.1186/s13287-017-0590-6. · DOI
  8. Weiss ML, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells. 2008;26(11):2865–74. https://doi.org/10.1634/stemcells.2007-1028. · DOI · Paper page
  9. Najar M, et al. Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: combined comparison of adipose tissue, Wharton’s jelly and bone marrow sources. Cell Immunol. 2010;264(2):171–9. https://doi.org/10.1016/j.cellimm.2010.06.006. · DOI · Paper page
  10. Zhou C, et al. Immunomodulatory effect of human umbilical cord Wharton’s jelly-derived mesenchymal stem cells on lymphocytes. Cell Immunol. 2011;272(1):33–8. https://doi.org/10.1016/j.cellimm.2011.09.010. · DOI · Paper page
  11. Yang H, Sun J, Wang F, Li Y, Bi J, Qu T. Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study. Oncotarget. 2016;7(45):72537–45. https://doi.org/10.18632/oncotarget.12345. · DOI
  12. Deng Y, et al. Umbilical cord-derived mesenchymal stem cells instruct monocytes towards an IL10-producing phenotype by secreting IL6 and HGF. Sci Rep. 2016;6:37566. https://doi.org/10.1038/srep37566. · DOI · Paper page
  13. Shin T-H, et al. Human umbilical cord blood-stem cells direct macrophage polarization and block inflammasome activation to alleviate rheumatoid arthritis. Cell Death Dis. 2016;7(12):e2524. https://doi.org/10.1038/cddis.2016.442. · DOI · Paper page
  14. Yin Y, et al. Human umbilical cord-derived mesenchymal stem cells direct macrophage polarization to alleviate pancreatic islets dysfunction in type 2 diabetic mice. Cell Death Dis. 2018;9(7):760. https://doi.org/10.1038/s41419-018-0801-9. · DOI
  15. Chatterjee D, et al. Human umbilical cord-derived mesenchymal stem cells utilize Activin-A to suppress interferon-γ production by natural killer cells. Front Immunol. 2014;5:662. https://doi.org/10.3389/fimmu.2014.00662. · DOI
  16. Che N, et al. Umbilical cord mesenchymal stem cells suppress B-cell proliferation and differentiation. Cell Immunol. 2012;274(1-2):46–53. https://doi.org/10.1016/j.cellimm.2012.02.004. · DOI
  17. Ribeiro A, et al. Mesenchymal stem cells from umbilical cord matrix, adipose tissue and bone marrow exhibit different capability to suppress peripheral blood B, natural killer and T cells. Stem Cell Res Ther. 2013;4(5):125. https://doi.org/10.1186/scrt336. · DOI · Paper page
  18. Deuse T, et al. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. Cell Transplant. 2011;20(5):655–67. https://doi.org/10.3727/096368910X536473. · DOI · Paper page
  19. Amable PR, Teixeira MVT, Carias RBV, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Res Ther. 2014;5(2):53. https://doi.org/10.1186/scrt442. · DOI · Paper page
  20. Prockop DJ, et al. Defining the risks of mesenchymal stromal cell therapy. Cytotherapy. 2010;12(5):576–8. https://doi.org/10.3109/14653249.2010.507330. · DOI · Paper page
  21. Lalu MM, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. https://doi.org/10.1371/journal.pone.0047559. · DOI · Paper page
  22. Thompson M, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis. EClinicalMedicine. 2020;19. https://doi.org/10.1016/j.eclinm.2019.100249. · DOI · Paper page
  23. Wang D, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17(3):333–40. https://doi.org/10.1007/s10238-016-0427-0. · DOI
  24. Hu J, et al. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60(3):347–57. https://doi.org/10.1507/endocrj.ej12-0343. · DOI · Paper page
  25. Sun L, et al. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010;62(8):2467–75. https://doi.org/10.1002/art.27548. · DOI · Paper page
  26. Li J-F, et al. The potential of human umbilical cord-derived mesenchymal stem cells as a novel cellular therapy for multiple sclerosis. Cell Transplantat. 2014;23(Suppl 1):S113–22. https://doi.org/10.3727/096368914X685005. · DOI · Paper page
  27. Riordan NH, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2018;16(1):57. https://doi.org/10.1186/s12967-018-1433-7. · DOI · Paper page
  28. Wang L, et al. Efficacy and safety of umbilical cord mesenchymal stem cell therapy for rheumatoid arthritis patients: a prospective phase I/II study. Drug Des Devel Ther. 2019;13:4331–40. https://doi.org/10.2147/DDDT.S225613. · DOI · Paper page
  29. Zhang J, Lv S, Liu X, Song B, Shi L. Umbilical cord mesenchymal stem cell treatment for Crohn’s disease: a randomized controlled clinical trial. Gut Liver. 2018;12(1):73–8. https://doi.org/10.5009/gnl17035. · DOI · Paper page
  30. Gao L, et al. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord–derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. JCO. 2016;34(24):2843–50. https://doi.org/10.1200/JCO.2015.65.3642. · DOI · Paper page
  31. Shi M, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med. 2017;6(12):2053–61. https://doi.org/10.1002/sctm.17-0134. · DOI · Paper page
  32. Sun Q, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial. J Transl Med. 2018;16(1):52. https://doi.org/10.1186/s12967-018-1422-x. · doi:10.1186/s12967-018-1422-x
  33. He X, et al. Umbilical cord-derived mesenchymal stem (stromal) cells for treatment of severe sepsis: a phase 1 clinical trial. Transl Res J Lab Clin Med. 2018;199:52–61. https://doi.org/10.1016/j.trsl.2018.04.006. · DOI
  34. Zhang Z, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS (London, England). 2013;27(8):1283–93. https://doi.org/10.1097/QAD.0b013e32835fab77. · DOI
  35. Wu Y, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132–8. https://doi.org/10.1016/j.scr.2013.10.001. · DOI
  36. Shu L, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. https://doi.org/10.1186/s13287-020-01875-5. · DOI · Paper page
  37. Lanzoni G, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: a double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021. https://doi.org/10.1002/sctm.20-0472. · DOI · Paper page
  38. Leng Z, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28. https://doi.org/10.14336/AD.2020.0228. · DOI · Paper page
  39. Nagamura-Inoue T, He H. Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells. 2014;6(2):195–202. https://doi.org/10.4252/wjsc.v6.i2.195. · DOI · Paper page
  40. Marmotti A, et al. Minced umbilical cord fragments as a source of cells for orthopaedic tissue engineering: an in vitro study. Stem Cells Int. 2012;2012:326813. https://doi.org/10.1155/2012/326813. · DOI
  41. Smith JR, Cromer A, Weiss ML. Human umbilical cord mesenchymal stromal cell isolation, expansion, cryopreservation, and characterization. Curr Protoc Stem Cell Biol. 2017;41:1F.18.1–1F.18.23. https://doi.org/10.1002/cpsc.24. · DOI
  42. Mendicino M, Bailey AM, Wonnacott K, Puri RK, Bauer SR. MSC-based product characterization for clinical trials: an FDA perspective. Cell Stem Cell. 2014;14(2):141–5. https://doi.org/10.1016/j.stem.2014.01.013. · DOI · Paper page
  43. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int. 2016;2016:6901286. https://doi.org/10.1155/2016/6901286. · DOI · Paper page
  44. Krampera M, Galipeau J, Shi Y, Tarte K, Sensebe L. Immunological characterization of multipotent mesenchymal stromal cells—the International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy. 2013;15(9):1054–61. https://doi.org/10.1016/j.jcyt.2013.02.010. · DOI · Paper page
  45. Galipeau J, et al. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151–9. https://doi.org/10.1016/j.jcyt.2015.11.008. · DOI · Paper page
  46. Mastrolia I, et al. Challenges in clinical development of mesenchymal stromal/stem cells: concise review. Stem Cells Transl Med. 2019;8(11):1135–48. https://doi.org/10.1002/sctm.19-0044. · DOI · Paper page
  47. Daly A. Remestemcel-L, the first cellular therapy product for the treatment of graft-versus-host disease. Drugs Today. 2012;48(12):773. https://doi.org/10.1358/dot.2012.48.12.1885866. · doi:10.1358/dot.2012.48.12.1885866
  48. Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L. Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy. 2018;20(11):1401–13. https://doi.org/10.1016/j.jcyt.2018.09.010. · DOI · Paper page

Cited by

See all 223

Metadata

Authors
Mebarki, M., Abadie, C., Larghero, J., & Cras, A.
Venue
Stem Cell Research & Therapy
Published
2021-02-26
Volume
12
Issue
1
Pages
152-152
ISSN
1757-6512 (ISSN-L)
OpenAlex
W3131068884
Cited by
223
References
4
FWCI
12.92
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products. https://app.cochat.ai/papers/10.1186/s13287-021-02222-y
The paper
Mebarki, M., Abadie, C., Larghero, J., & Cras, A. (2021). Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-021-02222-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.